INS and type 2 diabetes mellitus: The proportion of patients who initiated insulin was higher in the DPP-4i group than in the SGLT2i group (18% vs. 12%), which may have reduced the difference in LEA risk between treatment groups, as insulin is typically prescribed to patients with more severe type 2 diabetes and is associated with a fivefold increased risk of LEA [16].